Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

Los Angeles, California--(Newsfile Corp. - May 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accolade, Inc. ("Accolade" or "the Company") (NASDAQ: ACCD) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Accolade released its quarterly financial results on April 28, 2022. As part...

Investigation Notice: The Schall Law Firm Encourages Investors in Accolade, Inc. with Losses of $100,000 to Contact the Firm

Medication Integrated Care combines pharmacist-led medication therapy management with advanced analytics powered by Rx Savings Solutions to help employers reach individuals most likely to struggle with prescription complications and barriers to care. SEATTLE , May 3, 2022 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company that provides millions of individuals and their families with Personalized Healthcare, today announced the launch of Medication Integrated Care, an innovative offering for employers designed to address affordability, barriers to care and complications associated with prescription medications.

Accolade Launches Medication Integrated Care to Address Prescription Drug Costs and Complications

Today, investors in Accolade and ACCD stock have something to cheer, following a rather dismal end to last week. The post Why Is Accolade (ACCD) Stock Up Today?

Why Is Accolade (ACCD) Stock Up Today?

Wells Fargo upgrades Accolade to Equal Weight from Underweight, saying the stock's current price point creates a more balanced risk-and-reward profile.

Accolade Stock Rebounds. It's Upgraded on More Balanced Risk-Reward.

Accolade welcomes executive vice president and chief human resources officer Jennifer Hanson to create an amazing employee experience for the company that partners with human resource leaders to deliver Personalized Healthcare SEATTLE, May 2, 2022 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the appointment of Jennifer Hanson as chief human resources officer, executive vice president of people and culture, reporting to Accolade CEO, Rajeev Singh. Hanson will oversee Accolade's employee experience and engagement across the company's eight global offices, expanding innovative strategies to retain and attract exceptional talent at pace with the accelerated growth of the employer healthcare market.

Visionary Human Resources Leader Jennifer Hanson Joins Accolade

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Accolade, Inc. (NASDAQ: ACCD) resulting from allegations that Accolade may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Accolade securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th

ACCD EQUITY ALERT: Rosen Law Firm Encourages Accolade, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – ACCD

Accolade Inc (NASDAQ: ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million.

Why Are Accolade Shares Down Over 40% Today

Shares of Accolade Inc. lost nearly half their value Friday, after the personalized virtual health care services company reported a wider-than-expected fiscal fourth-quarter loss, and said it would lose its largest customer at the end of the year.

Accolade stock suffers record plunge after earnings miss, loss of largest customer

Accolade, Inc. (NASDAQ:ACCD ) Q4 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Todd Friedman - SVP, IR Rajeev Singh - CEO Steve Barnes - CFO Shantanu Nundy - Chief Medical Officer Conference Call Participants Michael Cherny - Bank of America Ryan Daniels - William Blair Jonathan Young - Credit Suisse Glen Santangelo - Jefferies Jeff Garro - Piper Sandler Ricky Goldwasser - Morgan Stanley Cindy Matson - Goldman Sachs Ryan MacDonald - Needham Sandy Draper - Guggenheim Stephanie Davis - SVB Securities Richard Close - Canaccord Genuity Operator Good day, and thank you for standing by. Welcome to the Accolade Fourth Quarter 2022 Earnings Conference Call.

Accolade, Inc. (ACCD) CEO Rajeev Singh on Q4 2022 Results - Earnings Call Transcript

SEATTLE, April 28, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal fourth quarter and full year ended February 28, 2022.

Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2022

SEATTLE, April 14, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal fourth quarter and full year 2022 financial results on Thursday, April 28, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Fourth Quarter and Full Year 2022 Financial Results

GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Priority Health, a nationally recognized nonprofit health plan, announced today a strategic partnership with Accolade (Nasdaq: ACCD), a Personalized Healthcare service, to bring a differentiated health care experience to Michigan employers in the commercial group market and their members. Priority Health and Accolade share a mission to help employees maximize their health plan benefits by creating a member experience uniquely tailored to each person's needs

Priority Health and Accolade Announce Strategic Partnership

New third-party research demonstrates how Accolade enhances employee retention and recruitment, overall experience and satisfaction, and perception of health insurance provider. SEATTLE , March 22, 2022 /PRNewswire/ -- Accolade (Nasdaq: ACCD), the company that provides millions of individuals and their families with Personalized Healthcare, announced today the findings of a new report that demonstrates the power of Personalized Healthcare in creating a positive employee experience in today's increasingly competitive talent economy.

Accolade Brings Proven Value to the Employee Experience Through Personalized Healthcare

SEATTLE, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Global Healthcare Conference, including a fireside chat presentation on Friday, February 18, 2022 at 2:20 p.m. E.T. A webcast will be available at ir.accolade.com.

Accolade to Participate in the 2022 SVB Leerink Global Healthcare Conference

SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in 24th Annual Needham Growth Conference, including a presentation on Friday, January 14, 2022 at 12:30 p.m. E.T. A webcast and related presentation materials will be available at ir.accolade.com.

Accolade to Participate in the 24th Annual Needham Growth Conference

The stock price of Accolade Inc (NASDAQ: ACCD) increased by over 20% during intraday trading today. This is why it happened.

Accolade Stock (ACCD): Why The Price Surged Today

Shares of Accolade Inc (NASDAQ: ACCD) opened about 25% up on Tuesday after the software and technology company reported better-than-expected financial results for its third quarter last night. Q3 results Accolade said its net income printed at $22.5 million in Q3 that translates to 31 cents per share.

Accolade surged 25% this morning: what's fuelling the stock?

Accolade Inc (NASDAQ: ACCD) reported Q3 FY22 sales of $83.5 million, up 117% Y/Y, beating the consensus of $75.89 million. The adjusted EBITDA loss widened to $(11.9) million, and the adjusted gross margin improved from 41.8% to 47%.

Accolade Shares Trade Higher After 117% Jump In Q3 Sales

Accolade, Inc.'s (ACCD) CEO Rajeev Singh on Q3 2022 Results - Earnings Call Transcript

SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal third quarter ended November 30, 2021.

Accolade Announces Results for Fiscal Third Quarter 2022

Accolade (ACCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Accolade (ACCD) Q3 Earnings Expected to Decline

Accolade went public in July 2020, raising $220 million in a U.S. IPO. The firm provides a healthcare information platform for enterprises and end users.

Accolade Impresses With Revenue Growth But Faces Operating Losses

SEATTLE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced that it will release fiscal third quarter 2022 financial results on Monday, January 10, 2022, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Third Quarter 2022 Financial Results

SEATTLE, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 400 employers and millions of members, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A presentation is available for registered attendees via the Piper Sandler conference site until December 2, 2021 or can also be accessed at ir.accolade.com.

Accolade to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

SEATTLE, Nov. 17, 2021 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD), the company that provides millions of people and their families with exceptional healthcare, announced today the expansion of its executive leadership team. The new leaders will help further Accolade's mission to empower people through expertise, empathy and technology to make the best decisions for their health and well-being.

News for Accolade Stock (ACCD)